Casgevy sales accelerate after toddler-age label
Q2 2026 revenue reached $76 million, 151% above the year-earlier quarter.
20 September 2026 · Alpha Briefing
Clinic
CRISPR in the clinic
22 clippings on the rack, newest printed 20 September 2026.
Earlier cuttings
Scribe starts first-in-human STX-1150 trial
The Phase 1 opened in Australia in mid-2026 in adults with elevated LDL-C and increased ASCVD risk.
4 Sept · The Biotech Times
One CTX310 infusion keeps lipid cuts at a year
Mean LDL cholesterol fell 53% at 12 months after a 0.8 mg/kg dose.
3 Sept · The Biotech Times
Highest CTX310 dose cuts ANGPTL3 78.6 percent at year one
Among the 4 participants who received the highest dose (0.8 mg/kg), the mean percent change from baseline at 1 year was -78.6% in ANGPTL3, -52.5% in LDL cholesterol, and -47.8% in triglycerides.
29 Aug · hcplive.com
Company IR: CTX310 durability heads to ESC and NEJM
On Aug. 28, 2026, CRISPR Therapeutics said Phase 1a CTX310 data showed 79% mean ANGPTL3 knockdown at the top dose at one year.
28 Aug · globenewswire.com
Small CRISPR cholesterol pilot reports year-long ~50% drop
The four people on the highest dose were part of a 15-patient safety study.
28 Aug · cnn.com
CTX310 lipid cuts hold at one year
In a phase 1a trial, one-time CRISPR-Cas9 gene editing with CTX310 was associated with no treatment-related dose-limiting toxic effects and with sustained reductions in ANGPTL3 and atherogenic lipids at 1 year.
28 Aug · nejm.org
CTX310 one-year lipid cuts reported from Phase 1a
A single intravenous infusion of CTX310 at the highest dose produced mean reductions from baseline of 79% for ANGPTL3, 48% for triglycerides, and 53% for low-density lipoprotein at one year.
28 Aug · investing.com
One infusion cuts cholesterol by half for a year
In the small study, which followed only 15 patients, participants who got the highest dose saw their cholesterol levels plunge by half — and stay that way for a year.
28 Aug · nytimes.com
One CRISPR infusion cut lipids at one year in small trial
Highest-dose patients had a 52.5% drop in LDL cholesterol from baseline at 12 months.
28 Aug · Cleveland Clinic
Mayo joins AEGIS as a trial site, not the lead
The clinic is a clinical collaborator on an ARPA-H award of up to $27.7 million.
27 Aug · News-Medical
Mayo Clinic joins ARPA-H AEGIS gene-editing programme
The five-year award is up to $27.7 million from the Advanced Research Projects Agency for Health.
27 Aug · newsnetwork.mayoclinic.org
Huidagene trial death splits reviewers of earlier talk
A young boy died in Huidagene’s gene editing trial last year.
19 Aug · STAT
VERVE-102 base edit cuts PCSK9 in first-in-human trial
One intravenous infusion of VERVE-102 produced dose-dependent mean PCSK9 reductions of 51% to 88% and LDL-cholesterol reductions of 9% to 62% in 35 adults.
13 Aug · pubmed.ncbi.nlm.nih.gov
SNIPR001 used under eIND for resistant E. coli malakoplakia
A 65-year-old kidney transplant patient received SNIPR001 after an emergency investigational new drug application; an intra-abdominal mass fell from 744.6 cm3 to 82 cm3 over a year.
12 Aug · clinicaltrialsarena.com
SNIPR001 phage cocktail used in malakoplakia
Intra-abdominal mass fell from 744.6 cm³ at baseline to 82 cm³ at one year.
11 Aug · academic.oup.com
CTX340 hypertension CRISPR trial opens as first-in-human Phase 1/2
NCT07758634 targets enrollment of 69 participants.
11 Aug · trial.medpath.com
CRISPR Therapeutics posts CASGEVY sales and new in vivo starts
CASGEVY generated second quarter 2026 revenue of $76 million; Phase 1 trials for CTX340 and CTX460 have been initiated.
3 Aug · sec.gov
VERVE-102 trial still recruiting after August registry update
Last Update Posted 2026-08-03 on NCT06164730; estimated enrollment 85, primary completion 2026-08.
3 Aug · clinicaltrials.gov
Casgevy sales jump as CRISPR pipeline enters more first-in-human work
On Aug. 3, 2026, CRISPR Therapeutics reported $76 million in second-quarter Casgevy revenue and new Phase 1 starts for CTX340 and CTX460.
3 Aug · globenewswire.com
Casgevy’s age floor drops to two
On July 31, 2026, 36Kr reported FDA’s Casgevy expansion to ages 2 and up after a 53-day CNPV review.
31 Jul · eu.36kr.com
Casgevy cleared down to age 2 for sickle cell and TDT
The U.S. Food and Drug Administration issued a supplemental approval for patients 2 years and older.
1 Jul · FDA
Five clippings on CRISPR in the clinic every morning, and you're done. iPhone.